Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial results has become “striking.” ・The fund urged the board to form a committee ...

Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Novavax raised its full-year 2025 revenue framework, now expecting adjusted total revenue between $1.04 billion and $1.06 ...

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...

US marketing authorization for its Covid-19 vaccine, Nuvaxovid to Sanofi, enabling Sanofi to take full responsibility for commercial and regulatory activities in the US and fulfilling part of its ...

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United ...

Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date ...